Welcome to our dedicated page for Cvs Health SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVS Health Corporation filings document formal disclosures for a NYSE-listed health care company with retail pharmacy, pharmacy benefit management, health insurance, clinic, specialty pharmacy, and consumer wellness operations. Recent Form 8-K reports furnish quarterly and annual operating results, financial guidance, investor-day materials, and material events tied to business performance.
The company's proxy materials and other filings describe board composition, director independence, committee assignments, executive compensation, stockholder voting matters, and governance practices. Additional 8-K disclosures record board leadership changes, common-stock registration information, and Omnicare subsidiary chapter 11 proceedings and related financing disclosures.
CVS Health executive vice president and Chief Experience & Technology Officer Tilak Mandadi sold 69,551 shares of CVS common stock in an open-market transaction. The shares were sold at an average price of about $89.58 per share, with prices ranging between $89.30 and $89.81. After this sale, Mandadi directly holds 10,133 CVS shares.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice reporting proposed sales of Common stock tied to restricted stock awards with multiple grant dates. The notice lists proposed quantities by grant date, including 20,229 and 20,449 share lots and additional smaller tranches, with transaction venue noted as NYSE.
CVS Health Corp filed a Form 13F reporting its institutional holdings. The filing lists 33 Form 13F information table entries with a total reported market value of $212,255,190. The report is signed by Michael Motolo and dated 05-07-2026.
CVS Health Corporation reported higher quarterly earnings on modest revenue growth. For the three months ended March 31, 2026, total revenues rose to $100.4 billion from $94.6 billion a year earlier, driven mainly by growth in pharmacy products and premiums across its Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments.
Net income attributable to CVS Health increased to $2.94 billion from $1.78 billion, with diluted earnings per share rising to $2.30 from $1.41. Operating income improved to $4.68 billion, reflecting higher operating margins and fewer large one‑time charges than in the prior year.
Cash and cash equivalents were $9.54 billion as of March 31, 2026, up from $8.45 billion at year-end 2025, while net cash provided by operating activities was $4.25 billion. Long-term debt remained sizable at about $60.5 billion, but total shareholders’ equity increased to $77.6 billion, supported by retained earnings growth and consistent quarterly dividends of $0.665 per share.
CVS Health Corporation reported strong first quarter 2026 results and raised its full-year outlook. Total revenues rose to $100.4 billion, up 6.2% from $94.6 billion a year earlier. GAAP diluted EPS increased to $2.30 from $1.41, while Adjusted EPS grew to $2.57 from $2.25, helped largely by much higher adjusted operating income in the Health Care Benefits segment and the absence of prior-year litigation and divestiture charges.
For 2026, CVS raised its GAAP diluted EPS guidance to a range of $6.24–$6.44 and Adjusted EPS to $7.30–$7.50. The company also increased its cash flow from operations guidance to at least $9.5 billion. Management highlighted improved performance in Health Care Benefits and contributions from its integrated health services model, while noting a continued cautious stance given elevated cost trends and potential macroeconomic headwinds.
Vanguard Capital Management reports beneficial ownership of 95,598,528 shares of CVS Health Corp common stock, representing 7.51% of the class as of 03/31/2026. The filing states sole voting power of 12,948,452 shares and sole dispositive power of 95,598,528 shares. The filing lists Vanguard Capital Management's address in Malvern, PA, and notes that the holdings include shares managed across Vanguard funds and client accounts. The filing is signed by Ashley Grim as Head of Global Fund Administration on 04/29/2026.
CVS Health Corporation is asking stockholders to elect 13 directors and approve key governance and compensation proposals at its virtual 2026 Annual Meeting. Items include director elections, auditor ratification, an advisory say-on-pay vote, and approval of a new 2026 Incentive Compensation Plan.
Management highlights 2025 financial performance, with $402.1 billion in revenue, $10.6 billion in operating cash flow and more than $3.0 billion returned to stockholders. The proxy details board refreshment, leadership changes including J. David Joyner as Chair and CEO, expanded stockholder outreach, and extensive use of AI and technology to improve care, efficiency and member experience.
CVS Health executive Prem S. Shah, EVP and Group President, reported equity compensation and related tax withholding transactions. On March 31, 2026, he received a grant of 161,676 stock options with a $71.82 exercise price, exercisable in three equal annual installments beginning March 31, 2027 and expiring on March 31, 2036. He also received 25,062 shares of restricted common stock, awarded as restricted stock units under the company’s 2017 Incentive Compensation Plan, with restrictions lapsing in three equal installments starting March 31, 2027. On April 1, 2026, 1,484 common shares were surrendered at $72.49 per share to cover withholding taxes due upon vesting and settlement of restricted stock units, rather than sold in the open market. Following these transactions, Shah directly holds 64,356.0985 common shares.
CVS Health EVP and CFO Brian Newman received new equity awards. He was granted stock options for 125,748 shares of common stock at an exercise price of $71.82 per share, which become exercisable in three equal annual installments starting on March 31, 2027.
Newman also received 19,493 restricted stock units of common stock at a reference price of $71.82 per share. These RSUs vest in three equal installments beginning on March 31, 2027. Following the RSU grant, he directly holds 41,354 shares of CVS Health common stock.